Sagimet Biosciences Inc.

SGMT

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001400118

None

No letter

2 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $116.5M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: dilution, distress, fortress balance sheet
Inputs computable	2 of 14
Graded from	filings received through Mar 11, 2026 241 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026
Last close	$9.87 2026-11-06; market equity $302.8M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 11, 2026

We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Our second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. The critical role of FASN overactivity in MASH makes it an attractive target for drug therapy.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 66.8						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	(3.9%)	(6.6%)	66.8	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 3.1					
Twelve-month failure probability	not computable	0.08%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	not computable	(0.37)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	22.82x	2.94x	3.1	828	2025-12-31
Growth and financing					
Revenue growth, three-year compound	not computable	10.0%			
four annual observations are required; found 1					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	not computable	2.2%			
four annual observations are required; found 3					
Net share issuance, one year	not computable	2.5%			
two annual share counts are required; found 1					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	2 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	16.0%	(2.1%)	59
Distance from 52-week high	(11.8%)	(30.5%)	73
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.85	0.29	82
Sales to price	0.01	0.30	5
Composite equity issuance, five years	not computable	21.4%	
Relative strength against the sector, log excess return	(0.02)	(0.19)	59

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$165.9M
Operating cash flow, four quarters	-$41.7M
Months of runway	47.7
Days since last periodic filing	88 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	$10.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$51.0M	2025-12-31	2026-03-11	10-K	26-026140
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$45.6M	2025-12-31	2026-03-11	10-K	26-026140
3	assets	us-gaap:Assets	$116.5M	2025-12-31	2026-03-11	10-K	26-026140
4	assets	us-gaap:Assets	$160.3M	2024-12-31	2026-03-11	10-K	26-026140
5	current assets	us-gaap:AssetsCurrent	$96.6M	2023-12-31	2025-03-12	10-K	25-002747
6	current liabilities	us-gaap:LiabilitiesCurrent	$5.7M	2023-12-31	2025-03-12	10-K	25-002747
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$249.7M	2023-12-31	2025-03-12	10-K	25-002747
8	operating income	us-gaap:OperatingIncomeLoss	-$30.7M	2023-12-31	2025-03-12	10-K	25-002747
9	book equity	us-gaap:StockholdersEquity	$91.1M	2023-12-31	2026-03-11	10-K	26-026140
10	assets	us-gaap:Assets	$96.7M	2023-12-31	2025-03-12	10-K	25-002747
11	liabilities	us-gaap:Liabilities	$5.7M	2023-12-31	2024-03-25	10-K	24-003812
12	current assets	us-gaap:AssetsCurrent	$116.4M	2025-12-31	2026-03-11	10-K	26-026140
13	current liabilities	us-gaap:LiabilitiesCurrent	$5.1M	2025-12-31	2026-03-11	10-K	26-026140
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.0M	2023-12-31	2025-03-12	10-K	25-002747
15	shares outstanding	us-gaap:CommonStockSharesOutstanding	0	2023-12-31	2024-03-25	10-K	24-003812

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.